CMC and post-approval changes MCQs With Answer

CMC and Post-Approval Changes MCQs With Answer is designed to help M. Pharm students consolidate critical aspects of Chemistry, Manufacturing, and Controls (CMC) and lifecycle change management in Regulatory Affairs (MPH 104T). This set focuses on ICH guidelines (Q8–Q12), FDA post-approval submission categories (PAS, CBE-30, CBE-0, Annual Report), EU Variations (Type IA/IB/II), SUPAC principles, comparability for biologics, and supportive data such as stability, dissolution, and extractables/leachables. Each MCQ probes practical, decision-critical nuances—how to classify a change, what data are expected, and how Pharmaceutical Quality Systems (PQS) and risk management shape regulatory strategy. Use these questions to test readiness for real-world regulatory submissions and robust lifecycle management.

Q1. Which ICH guideline primarily addresses pharmaceutical development concepts such as QTPP, CQA, CPP, design space, and control strategy?

• ICH Q8(R2) Pharmaceutical Development
• ICH Q7 Good Manufacturing Practice
• ICH Q1A(R2) Stability Testing
• ICH E6(R2) Good Clinical Practice

Correct Answer: ICH Q8(R2) Pharmaceutical Development

Q2. In the US, which submission type is generally required for a major post-approval change with substantial potential to adversely affect product quality?

• Annual Report
• CBE-0 Supplement
• CBE-30 Supplement
• Prior Approval Supplement (PAS)

Correct Answer: Prior Approval Supplement (PAS)

Q3. Which US reporting category is appropriate for a minor change with minimal potential to adversely affect the identity, strength, quality, purity, or potency of the product?

• Annual Report (AR)
• CBE-30 Supplement
• CBE-0 Supplement
• Prior Approval Supplement (PAS)

Correct Answer: Annual Report (AR)

Q4. SUPAC-IR provides guidance for post-approval changes to immediate-release solid oral dosage forms. Which of the following is NOT a SUPAC-IR change category?

• Components and Composition
• Manufacturing Site
• Scale-Up and Post-Approval Changes in Equipment/Process
• Pharmacovigilance Reporting Requirements

Correct Answer: Pharmacovigilance Reporting Requirements

Q5. Under the EU Variations Regulation (EC) No 1234/2008, which variation type requires prior assessment and approval before implementation?

• Type IA
• Type IA(IN)
• Type IB
• Type II

Correct Answer: Type II

Q6. Under ICH Q12, PACMP stands for which of the following?

• Post-Approval Control and Monitoring Plan
• Process Analytical Control Management Plan
• Post-Approval Change Management Protocol
• Product and Component Management Procedure

Correct Answer: Post-Approval Change Management Protocol

Q7. A change in sterilization method (e.g., from moist heat to gamma) for an aseptically processed product typically triggers which US submission category?

• Annual Report
• CBE-0 Supplement
• CBE-30 Supplement
• Prior Approval Supplement (PAS)

Correct Answer: Prior Approval Supplement (PAS)

Q8. For biotechnology-derived products, demonstrating product comparability after a manufacturing change is primarily guided by which ICH guideline?

• ICH Q5E
• ICH Q3A/B
• ICH M7(R1)
• ICH S9

Correct Answer: ICH Q5E

Q9. To justify extension of a product’s shelf-life, which stability data are generally expected by regulators?

• Accelerated stability data only
• Stress (forced degradation) data only
• Long-term real-time data at proposed storage conditions demonstrating acceptable trends
• No additional data if release results meet all specifications

Correct Answer: Long-term real-time data at proposed storage conditions demonstrating acceptable trends

Q10. Under ICH Q8, movement within an approved design space is generally considered:

• A change requiring a Prior Approval Supplement
• A Type II variation in the EU
• Not a regulatory post-approval change; manage within the Pharmaceutical Quality System
• A change needing prior Type IB notification

Correct Answer: Not a regulatory post-approval change; manage within the Pharmaceutical Quality System

Q11. In the US, a Comparability Protocol is best described as:

• A pharmacovigilance plan for signal detection after approval
• A pre-agreed plan that defines tests, acceptance criteria, and reporting category for future changes to streamline review
• An abbreviated NDA pathway for generic products
• An expedited inspection procedure for new manufacturing sites

Correct Answer: A pre-agreed plan that defines tests, acceptance criteria, and reporting category for future changes to streamline review

Q12. In the EU, a change of manufacturing site for a biological drug substance is generally classified as:

• Type IA
• Type IA(IN)
• Type IB
• Type II

Correct Answer: Type II

Q13. Which statement best defines a Critical Quality Attribute (CQA)?

• A process parameter that must be tightly controlled to avoid deviation
• A physical, chemical, biological, or microbiological characteristic that must be within limits to ensure product quality
• An approved specification agreed upon with regulators for batch release
• A marketing claim that reflects product performance

Correct Answer: A physical, chemical, biological, or microbiological characteristic that must be within limits to ensure product quality

Q14. Which quality risk management tool is most commonly used to assess impact and detectability for proposed CMC changes?

• FMEA (Failure Mode and Effects Analysis)
• DOE (Design of Experiments)
• GLP (Good Laboratory Practice)
• BPR (Batch Production Record)

Correct Answer: FMEA (Failure Mode and Effects Analysis)

Q15. Which ICH guideline defines validation characteristics and acceptance criteria for analytical procedures used to support CMC changes?

• ICH Q2(R2)
• ICH Q11
• ICH M7(R1)
• ICH S6(R1)

Correct Answer: ICH Q2(R2)

Q16. When changing the container-closure system for a parenteral product, which dataset is most critical to support the change?

• Updated Certificate of Analysis for the stopper only
• Extractables/leachables assessment and container-closure integrity (CCI) data under worst-case conditions
• Revalidation of the ERP system
• Bioequivalence study in healthy volunteers

Correct Answer: Extractables/leachables assessment and container-closure integrity (CCI) data under worst-case conditions

Q17. For a CBE-30 supplement in the US, when may a sponsor implement the change?

• Immediately upon submission
• 30 calendar days after FDA receipt of the supplement if no objection is raised
• Only after an FDA approval letter is issued
• 60 calendar days after FDA receipt of the supplement

Correct Answer: 30 calendar days after FDA receipt of the supplement if no objection is raised

Q18. For a Type IA variation in the EU, when should the marketing authorization holder notify the authority?

• Before implementation
• Within 12 months following implementation
• Immediately after implementation for all Type IA (including IA and IA(IN))
• No notification is required

Correct Answer: Within 12 months following implementation

Q19. Which element of ICH Q10 is central to evaluating, documenting, and approving post-approval CMC changes within the PQS?

• Corrective and Preventive Action (CAPA) system
• Management Review
• Change Management System
• Deviation Management

Correct Answer: Change Management System

Q20. After certain post-approval changes to an oral solid dosage form, which statistical metric is commonly used to compare dissolution profiles between pre- and post-change batches?

• f1 difference factor
• f2 similarity factor
• T50 (time to 50% dissolved)
• RSD of assay results

Correct Answer: f2 similarity factor

Download